Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
| Revenue (TTM) | $1.06B |
| Gross Profit (TTM) | $115.73M |
| EBITDA | $-338.65M |
| Operating Margin | -47.70% |
| Return on Equity | -67.60% |
| Return on Assets | -7.03% |
| Revenue/Share (TTM) | $6.55 |
| Book Value | $2.96 |
| Price-to-Book | 19.02 |
| Price-to-Sales (TTM) | 8.74 |
| EV/Revenue | 8.95 |
| EV/EBITDA | 135.77 |
| Quarterly Earnings Growth (YoY) | -43.70% |
| Quarterly Revenue Growth (YoY) | 87.00% |
| Shares Outstanding | $165.26M |
| Float | $163.96M |
| % Insiders | 0.61% |
| % Institutions | 107.19% |
Volatility is currently contracting
Ionis Pharmaceuticals NASDAQ: IONS reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch progress for TRYNGOLZA in severe hypertriglyceridemia.
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to earnings of $0.86 per share a year ago.
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.
SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IONS and any ticker you trade — then tracks every position and per-strategy win rate.
